Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy: BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling positive-like symptoms of schizophrenia
Food and Drug Administration (FDA) to treat type 2 diabetes include: Three GLP-1 drugs are also FDA-approved to treat obesity regardless of whether a person has type 2 diabetes
RhoA-mediated inhibition of vascular endothelial cell mobility: Positive feedback through reduced cytosolic p21 and p27
Any promotional activity, including so-called awareness campaigns, that functions as a surrogate advertisement for prescription-only drugs shall be viewed seriously and may be treated as irrational or misleading marketing practice, stated Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India
and LOKHANDWALA, Y., 1999
Ghrelin agonist ipamorelin effects on the HPT axis